Abstract 1550
Background
There is scarce data of the impact of inflammatory indexes in locally advanced NSCLC, which is a highly heterogeneous illness. Choice of therapy is complex and often, combined CRT, either concurrently or sequentially is used. We aim to determine the impact of NLR monitoring in patients with stage III NSCLC treated with CRT.
Methods
Patients with stage III NSCLC treated with CRT were identified from Jan2010 to Dec2015 in our centre. NLR (neutrophils/lymphocytes) was retrospectively collected at baseline (B) and 5-6 weeks after CRT (C). It was considered a continuous variable and categorised (low <4, high ≥4). NLR monitoring (B and C) stratified 2 groups: good (NLR remained <4 and NLR decreased ≥4 to < 4) and poor (NLR increased <4 to ≥ 4 and NLR remained ≥4). Progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier method and log-rank test. Cox regression model was used for the multivariate analysis.
Results
92 patients were included; median age 65.5 years (39-83); 85.87% were male and 90.3% had ECOG 0-1. Predominant histologies: adenocarcinoma (41.3%) and squamous-cell carcinoma (56.5%). Concurrent treatment in 78.9% patients and sequential in 21.1%. Median PFS and OS were 16.23 and 30.36 months (mo), in the overall population. On the multivariate analysis, the good prognostic group had significant longer median PFS and OS than the poor group: 33.9 vs 11.1 mo (p<.001) and 48.8 vs 17.4 mo (p<.001), respectively. Higher post-treatment NLR was also associated with shorter PFS and OS.Table:
1466P
Multivariate analysis | ||||
---|---|---|---|---|
PFS | OS | |||
HR (95% CI) | p value | HR (95% CI) | p value | |
ECOG | 1.65 (0.81 – 3.38) | 0.169 | 2.55 (1.17 – 5.56) | 0.018 |
Sequiential vs. Concurrent CRT | 0.87 (0.41 – 1.81) | 0.703 | 0.87 (0.38 – 1.97) | 0.732 |
Baseline NLR | 1.01 (0.83 – 1.23) | 0.918 | 0.84 (0.66 – 1.07) | 0.158 |
Post CRT NLR (low vs high) | 1.08 (1.01 – 1.15) | 0.018 | 1.11 (1.05 – 1.19) | <0.001 |
Prognostic groups (good vs poor) | 3.00 (1.49 – 6.02) | 0.002 | 2.83 (1.30 – 6.14) | 0.009 |
Conclusions
NLR could be used as a prognostic factor in stage III NSCLC especially when considering its dynamic evolution. Our results provide the opportunity to evaluate this inexpensive and reproducible index as a prognostic or predictive biomarker in prospective studies, particularly with the novel use of anti-PD-1/L1 after CRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Universitario Doctor Peset.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract